Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study

Ophthalmology

Volumn 121, Issue 2, 2014, Pages 535-544

  Chew, Emily Y ^a   Clemons, Traci E ^b   Bressler, Susan B ^c   Elman, Michael J ^d   Danis, Ronald P ^e   Domalpally, Amitha ^e   Heier, Jeffrey S ^f   Kim, Judy E ^g   Garfinkel, Richard ^h  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Elman Retina Group   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h Retina Group of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; FUNDUS CAMERA; GENERAL DEVICE; HIGH RISK PATIENT; HOME MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERIMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SELF MONITORING; SUBRETINAL NEOVASCULARIZATION; TELEMONITORING; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PROSPECTIVE STUDIES; TELEMEDICINE; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84893439058     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.10.027     Document Type: Article

References (26)

1. Eye Diseases Prevalence Research Group Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 2004 477 485
2. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
3. D. Pascolini, S.P. Mariotti, and G.P. Pokharel et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies Ophthalmic Epidemiol 11 2004 67 115
4. G.S. Ying, J. Huang, M.G. Maguire Comparison of Age-related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
5. P.K. Kaiser, D.M. Brown, and K. Zhang et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results Am J Ophthalmology 144 2007 850 857
6. CATT Research Group; Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovscular age-related macular degeneration. N Engl J Med 2011;365:1897-908.
7. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
8. IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
9. J.S. Heier, D.M. Brown, and V. Chong et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
10. D.S. Boyer, A.N. Antoszyk, C.C. Awh MARINA Study Group Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252
11. D.S. Fong, P. Custis, J. Howes, and J.W. Hsu Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multi-center, retrospective study Ophthalmology 117 2010 298 302
12. R. Rauch, B. Weingessel, S.M. Maca, and P.V. Vecsei-Marlovits Time to first treatment: the significance of early treatment of exudative age-related macular degeneration Retina 32 2012 1260 1264
13. A.R.E.D.S.2 Research Group, E.Y. Chew, T. Clemons, and J.P. SanGiovanni et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1) Ophthalmology 119 2012 2282 2289
14. Age-Related Eye Disease Study 2 (AREDS2) Research Group Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial JAMA 309 2013 2005 2015
15. G. Westheimer Visual acuity and hyperacuity Invest Ophthalmol 145 1975 570 572
16. A. Loewenstein, J.R. Ferencz, and Y. Lang et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device Retina 30 2010 1058 1064
17. R.W. Beck, P.S. Moke, and A.H. Turpin et al. A computerized method of visual acuity testing: an adaptation of the Early Treatment Diabetic Retinopathy Study testing protocol Am J Ophthalmol 135 2003 194 205
18. P.H. van Elteren On the combination of independent two-sample tests of Wilcoxon Bull Int Stat Inst 37 1960 351 361
19. M. Stur, and Y. Manor Long-term monitoring of age-related macular degeneration with preferential hyperacuity perimetry Ophthalmic Surg Lasers Imaging 41 2010 598 606
20. A.M. Fine, M.J. Elman, and J.E. Ebert et al. Earliest symptoms caused by neovascular membranes in the macula Arch Ophthalmol 104 1986 513 514
21. R. Trevino, and M.G. Kynn Macular function surveillance revisited Optometry 79 2008 397 405
22. D.L. Isaac, M.P. de Avila, and A.P. Cialdini Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration Arq Bras Oftalmol 70 2007 771 776
23. G. Querques, L. Querques, and O. Rafaeli et al. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab Invest Ophthalmol Vis Sci 52 2011 7012 7018
24. R. Das, Y. Shi, G. Silvestri, and U. Chakravarthy Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy Retina 29 2009 1013 1018
25. American Academy of Ophthalmology Retina/Vitreous Panel Preferred Practice Pattern Guidelines. Age-Related Macular Degeneration 2008 American Academy of Ophthalmology San Francisco, CA 16 Available at: http://one.aao.org/ guidelines-browse?filter=preferredpracticepatterns Accessed October 16, 2013
26. F.A. Sloan, G. Picone, D.S. Brown, and P.P. Lee Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status Am Geriatr Soc 53 2005 1867 1874